CTI Clinical Trial and Consulting Services
(CTI) announces the expansion of its offices in Cincinnati, Ohio (Global Headquarters); Raleigh, North Carolina; Madrid, Spain; and Ulm, Germany (European Headquarters).
“This reflects continued growth of the company due to new business awards from our current pharmaceutical and biotechnology sponsors,” according to Timothy J. Schroeder, CTI CEO and President. “We are very fortunate to have long term relationships with these sponsors, in some cases for more than a decade, and they continue to partner with us. We are extremely grateful for the opportunities.”
CTI currently works with more than 60 pharmaceutical and biotechnology companies, including eight of the ten largest global companies. These office expansions will allow for expanded capabilities and additional personnel across all departments.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.